Insight Molecular Diagnostics Inc.
NASDAQ:IMDXMedical - Diagnostics & Research
+$0.13 today
- Market cap
- $52.08M
- Beta
- 1.79
- P/E (TTM)
- -3.9
- EPS (TTM)
- -$1.39
Volume 0.64M
Average 0.38M
IMDX Total Non-current Liabilities
All obligations due after more than one year.
Insight Molecular Diagnostics Inc.NASDAQ: IMDX
Total Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total non-current liabilities falls 3.3% from a year ago
Total non-current liabilities stood at $39.11M at the end of Q1 FY2026, down 3.3% from a year earlier and down 13.4% from the prior quarter. Over 3 fiscal years it compounded at -2.3% a year.
Context
- Total non-current liabilities amounted to 96.7% of total assets at the end of Q1 FY2026, up 29.7 pp from a year earlier.
- Total non-current liabilities increased in 1 of the last 3 fiscal years.
What to watch
Whether total non-current liabilities keeps falling in the next quarterly balance sheet after a -3.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 45.15M USD
- Year-over-year change
- +12.6%
- 4-year CAGR
- -13.4%
| Period | Period end | Total Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 45.15M | +12.6% |
| FY2024 | 2024-12-31 | 40.08M | -15.1% |
| FY2023 | 2023-12-31 | 47.23M | -2.4% |
| FY2022 | 2022-12-31 | 48.39M | -39.7% |
| FY2021 | 2021-12-31 | 80.23M | — |
Total Non-current Liabilities vs competitors
How IMDX compares with its peers on the latest reported figures
- IMDX's Mar 2026 total non-current liabilities of $39.11M is the 5th highest of the 10 companies compared; the peer median is $25.79M.
- Its year-over-year change of -3.3% is the 5th highest of 9, against a peer median of -7.5%.
- Total non-current liabilities amounts to 96.7% of total assets for IMDX, versus a peer median of 20.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $372.16M | +1120.5% | +82.8% | 533.2% | |
| Mar 2026 | $136.74M | +148.4% | +207.1% | 70.6% | |
| Mar 2026 | $71.29M | +22.2% | +8.4% | 55.1% | |
| Mar 2026 | $67.37M | -19.4% | -10.6% | 20.5% | |
IMDXInsight Molecular Diagnostics Inc. | Mar 2026 | $39.11M | -3.3% | -2.3% | 96.7% |
| Mar 2026 | $25.79M | -18.7% | -41.3% | 43.0% | |
| Mar 2026 | $17.74M | -3.0% | +80.3% | 14.8% | |
| Mar 2026 | $17.44M | -18.0% | -31.1% | 5.9% | |
| Mar 2026 | $13.35M | -11.9% | -10.0% | 8.5% | |
| Mar 2026 | $7.03M | — | -18.3% | 2.9% | |
| Peer median (excluding IMDX) | $25.79M | -7.5% | -10.0% | 20.5% | |
Competitors are the stored peer set for IMDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 32.95M | 19.99M | 9.43M | 8.64M | 11.58M |
| Short-term Investments | 904K | 433K | 0 | 0 | 0 |
| Net Receivables | 1.44M | 2.01M | 484K | 1.61M | 1.13M |
| Inventory | 304K | 0 | 0 | 410K | 446K |
| Other Current Assets | 2.94M | 2.12M | 782K | 1.1M | 2.15M |
| Total Current Assets | 39.14M | 25.54M | 10.7M | 11.76M | 15.31M |
| Property, Plant & Equipment (Net) | 8.37M | 10.85M | 5.44M | 2.76M | 2.82M |
| Goodwill | 18.68M | 0 | 0 | 0 | 0 |
| Intangible Assets | 61.72M | 61.63M | 56.6M | 14.61M | 0 |
| Long-term Investments | 0 | 0 | 0 | 1.7M | 607K |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 31.65M | 2.07M | 2.16M | 4.26M | 7.03M |
| Total Non-current Assets | 120.42M | 74.56M | 64.19M | 23.32M | 10.45M |
| Total Assets | 159.56M | 100.09M | 74.89M | 35.08M | 25.76M |
| Account Payables | 1.81M | 1.25M | 953K | 2.28M | 2.54M |
| Short-term Debt | 1.31M | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 6.71M | 4.43M | 4.01M | 2.17M | 2.89M |
| Total Current Liabilities | 14.12M | 12.11M | 7.19M | 7.28M | 12.08M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 76.68M | 45.66M | 45.03M | 37.71M | 43.46M |
| Total Non-current Liabilities | 80.23M | 48.39M | 47.23M | 40.08M | 45.15M |
| Total Liabilities | 94.35M | 60.5M | 54.42M | 47.36M | 57.22M |
| Common Stock | 252.95M | 294.93M | 310.3M | 338.24M | 369.21M |
| Retained Earnings | (187.77M) | (260.68M) | (289.88M) | (350.54M) | (400.76M) |
| Accumulated OCI | 37K | 39K | 49K | 21K | 86K |
| Other Stockholders Equity | 0 | (0) | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 65.22M | 39.59M | 20.47M | (12.27M) | (31.46M) |
| Total Debt | 5.68M | 3.54M | 2.87M | 3.66M | 3.5M |
| Net Debt | (27.27M) | (16.45M) | (6.56M) | (4.97M) | (8.09M) |
Insight Molecular Diagnostics Inc.
NASDAQ:IMDX
Intrinsic Alpha fair value
Locked
Current Price
$1.59
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.